These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7870241)

  • 1. Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis.
    Bedani PL; Perini L; Gilli P
    Nephron; 1994; 68(4):512-3. PubMed ID: 7870241
    [No Abstract]   [Full Text] [Related]  

  • 2. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
    Weissgarten J; Zaidenstein R; Fishman S; Dishi V; Michovitz-Koren M; Averbukh Z; Golik A
    Perit Dial Int; 1999; 19(2):180-2. PubMed ID: 10357195
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.
    Yang KC; Fang CC; Su TC; Lee YT
    Am J Kidney Dis; 2005 Mar; 45(3):e57-60. PubMed ID: 15754265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rhabdomyolysis and acute renal failure secondary to statins].
    Borrego FJ; Liébana A; Borrego J; Pérez del Barrio P; Gil JM; García Cortés MJ; Sánchez Perales C; Serrano P; Pérez Bañasco V
    Nefrologia; 2001; 21(3):309-13. PubMed ID: 11471312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bezafibrate myopathy in two patients with chronic renal failure].
    Inoue M; Jimi T; Machida H; Niwa Y; Wakayama Y
    Rinsho Shinkeigaku; 1992 Jul; 32(7):725-8. PubMed ID: 1291164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
    Kamaliah MD; Sanjay LD
    Singapore Med J; 2001 Aug; 42(8):368-72. PubMed ID: 11764054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of toxicity of bezafibrate in hemodialysis patients.
    Keller F; Faber U; Reeck S
    Clin Nephrol; 1987 Sep; 28(3):159-60. PubMed ID: 3665213
    [No Abstract]   [Full Text] [Related]  

  • 9. [A case of acute rhabdomyolysis and acute renal insufficiency caused by the simultaneous use of furosemide and bezafibrate].
    Venzano C; Cordi GC; Corsi L; Dapelo M; De Micheli A; Grimaldi GP
    Minerva Med; 1990 Dec; 81(12):909-11. PubMed ID: 2280884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate].
    Sugie M; Kuriki A; Arai D; Ichikawa H; Kawamura M
    No To Shinkei; 2005 Sep; 57(9):785-90. PubMed ID: 16248366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone scintigraphy of drug-induced rhabdomyolysis: antihyperlipidemia agent.
    Takayama T; Tsuji S; Taki J; Michigishi T; Tonami N
    Clin Nucl Med; 1996 Dec; 21(12):988-9. PubMed ID: 8957627
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bezafibrate-induced rhabdomyolysis in a patient with impaired kidney function].
    Haubenstock A; Schmidt P; Zazgornik J; Balcke P; Kopsa H; Sertl K
    Dtsch Med Wochenschr; 1984 Jan; 109(4):157-8. PubMed ID: 6692783
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute rhabdomyolysis associated with digestive disorders during a voluntary overdose of ciprofibrate].
    Giraud O; Chanu B; Farge D; Parrot F; Brestescher C; Rouffy J
    Gastroenterol Clin Biol; 1995 Feb; 19(2):231-2. PubMed ID: 7750722
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood monitoring of bezafibrate in a chronic hemodialysis patient.
    Takeda K; Nakamoto M; Yasunaga C; Nishihara G; Matsuo K; Urabe M; Goya T
    Nephron; 1997; 76(4):487-8. PubMed ID: 9274850
    [No Abstract]   [Full Text] [Related]  

  • 15. [Case of secondary carnitine deficiency (in a patient undergoing hemodialysis), developing rhabdomyolysis due to dehydration and the action of a hypolipemic agent].
    Kawashima N; Shindo R; Fusegawa H; Sato F
    Nihon Naika Gakkai Zasshi; 1993 Dec; 82(12):2066-7. PubMed ID: 8294807
    [No Abstract]   [Full Text] [Related]  

  • 16. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil.
    Knoll RW; Ciafone R; Galen M
    Conn Med; 1993 Sep; 57(9):593-4. PubMed ID: 8252847
    [No Abstract]   [Full Text] [Related]  

  • 17. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment.
    Górriz JL; Sancho A; Alcoy E; García-Ramos JL; Pallardó LM
    Nephrol Dial Transplant; 1995 Dec; 10(12):2371-2. PubMed ID: 8808248
    [No Abstract]   [Full Text] [Related]  

  • 18. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
    Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
    Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants.
    de Alava E; Sola JJ; Lozano MD; Pardo-Mindán FJ
    Nephron; 1994; 66(2):242-3. PubMed ID: 8139752
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function].
    Rumpf KW; Barth M; Blech M; Kaiser H; Koop I; Arnold R; Scheler F
    Klin Wochenschr; 1984 Apr; 62(8):346-8. PubMed ID: 6727274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.